CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 444 filers reported holding CRISPR THERAPEUTICS AG in Q1 2022. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,051 | -30.6% | 23,163 | -14.2% | 0.01% | +9.1% |
Q2 2023 | $1,515 | +26.6% | 26,981 | +2.0% | 0.01% | -21.4% |
Q1 2023 | $1,197 | +7.7% | 26,460 | -3.2% | 0.01% | 0.0% |
Q4 2022 | $1,111 | -99.9% | 27,333 | +112.9% | 0.01% | +40.0% |
Q3 2022 | $839,000 | -78.2% | 12,840 | -79.7% | 0.01% | -75.6% |
Q2 2022 | $3,841,000 | +1276.7% | 63,212 | +1321.5% | 0.04% | +1950.0% |
Q1 2022 | $279,000 | -84.1% | 4,447 | -80.8% | 0.00% | -80.0% |
Q4 2021 | $1,754,000 | -78.2% | 23,150 | -67.8% | 0.01% | -73.7% |
Q3 2021 | $8,054,000 | -18.1% | 71,956 | +18.5% | 0.04% | -17.4% |
Q2 2021 | $9,830,000 | +35.1% | 60,722 | +1.7% | 0.05% | +21.1% |
Q1 2021 | $7,276,000 | +786.2% | 59,710 | +1013.2% | 0.04% | +850.0% |
Q4 2020 | $821,000 | +42.0% | 5,364 | -22.3% | 0.00% | 0.0% |
Q3 2020 | $578,000 | -6.0% | 6,907 | -17.5% | 0.00% | -20.0% |
Q2 2020 | $615,000 | +53.4% | 8,371 | +27.1% | 0.01% | +25.0% |
Q4 2019 | $401,000 | -47.1% | 6,585 | -64.4% | 0.00% | -33.3% |
Q3 2019 | $758,000 | – | 18,504 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |